 SYDNEY , Sept. 8, 2022 PRNewswire -- Kazia Therapeutics Limited NASDAQ: KZIA; ASX: KZA, an oncology-focused drug development company, today announced that final data from its phase II study of paxalisib in patients with newly diagnosed glioblastoma will be the subject of an oral presentation at the upcoming annual congress of the European Society for Medical Oncology ESMO, which will be held in person from 9-13 September 2022 in Paris, France. 